title: The role of angiogenesis in neuroendocrine tumors.
abstract: The first studies to assess in vitro angiogenesis in neuroendocrine tumors used animal-based assays to study the antiangiogenic properties of somatostatin analogs. Current technologies enable investigators to directly appraise the in vitro angiogenic response of an individual's neuroendocrine tumor with and without potential antiangiogenic reagents. This article describes the evolution of methods to assess in vitro angiogenesis in neuroendocrine tumors and describes some of the clinical data.
authors.affiliation: Department of Surgery, Louisiana State University, Health Sciences Center, New Orleans, LA 70112, USA.
authors.forename: John
authors.initials: J
authors.lastname: Lyons
authors.forename: Catherine T
authors.initials: CT
authors.lastname: Anthony
authors.forename: Eugene A
authors.initials: EA
authors.lastname: Woltering
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D006801:Humans; D008954:Models, Biological; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000235:genetics / Q000503:physiopathology*; D018358:Neuroendocrine Tumors / Q000098:blood supply* / Q000188:drug therapy / Q000209:etiology* / Q000235:genetics; D017481:Receptors, Somatostatin / Q000235:genetics / Q000502:physiology; D013004:Somatostatin / Q000031:analogs & derivatives / Q000235:genetics / Q000627:therapeutic use
chemical_list: D020533:Angiogenesis Inhibitors; D017481:Receptors, Somatostatin; D013004:Somatostatin